Resminostat: Preliminary Phase II data

Preliminary data from the first 9 patients in the ongoing, open-label, German Phase II SHELTER trial showed that oral 4SC-201 alone or in combination with Nexavar sorafenib produced 6 cases of stable disease according to RECIST criteria at week 6. Three of 4 evaluable patients maintained stable disease at week 12, and 1 patient in the combination arm maintained stable disease at week 36. ...